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Dear editor,
With great interest we read the review of Alfieri et al. [1] con-
cerning systemic therapies in metastatic salivary gland carcino-
mas. In addition to this, we hereby present our experience with
novel HER2-targeted therapies in metastatic salivary duct carci-
noma (SDC) patients.
SDC is a rare and aggressive subtype of salivary gland cancer,
with a median overall survival (OS) of 3–4 years after primary
diagnosis [2–4]. As stated in the above mentioned review,
responses to chemotherapy are poor and knowledge about new
drugs is based on small studies. Next to this, many studies
‘‘lumped” patients with a spectrum of salivary gland cancers, fail-
ing to fully appreciate the impact of the heterogeneity in salivary
gland cancer [5].
In SDC, HER2 is overexpressed in 21–44% [4,6,7] of the cases,
and could serve as a therapeutical target [8]. In Table 1 we show
the available evidence on HER2-targeted therapies for metastatic
SDC. The most important study is a phase II clinical trial in 45
patients treated with docetaxel and trastuzumab for advanced
HER2-positive SDC, in which preliminary results show an overall
response rate of 69% and a median progression free survival
(PFS) of 11.3 months [9].
In breast cancer, patients receiving docetaxel and trastuzumab
for HER2-positive metastatic breast cancer have a median PFS of
12.4 months and median OS of 40.8 months. Adding pertuzumab
to this regimen extents the median PFS and OS to 18.7 and
56.5 months, respectively [10]. Because of similarities in histology
and HER2 status, we hypothesized that adding pertuzumab may
also increase PFS in SDC. In this letter to the editor we describe
two patients treated with the combination of docetaxel, trastuzu-
mab and pertuzumab in our clinic. Additionally, we demonstrate
in one patient that after disease progression another line of
HER2-targeted therapy with trastuzumab-emtansine can be
beneficial.
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Both patients were treated with the combination of docetaxel,
trastuzumab and pertuzumab. Docetaxel was dosed 75 mg/m2
intravenously (IV) every 3 weeks. The HER2-targeting monoclonal
antibodies trastuzumab and pertuzumab were dosed 600 mg sub-
cutaneously and 420 mg IV every 3 weeks, respectively. For per-
tuzumab, patients received a loading dose of 840 mg in the first
cycle. After 6 cycles docetaxel was stopped and trastuzumab and
pertuzumab were continued until PD. After PD, one patient was
treated with trastuzumab-emtansine. This is an antibody-drug
conjugate consisting of trastuzumab linked to the microtubule
inhibitor emtansine. It was dosed 3.6 mg/kg IV every 3 weeks.
Case 1. A 63-year-old man was diagnosed with a pT3N2bM0
androgen receptor (AR) positive SDC of the right parotid gland
and primary treatment consisted of a parotidectomy with a modi-
fied neck dissection of level I–V, followed by adjuvant radiation
therapy (66 Gy in fractions of 2 Gy). Only 8 months later, patient
was diagnosed with metastases in liver, lungs and mediastinal
lymph nodes for which palliative androgen deprivation therapy
(ADT) was started. After 6 months, the patient had PD and ADT
was stopped. Because HER2 was strongly positive (immunohisto-
chemistry (IHC) 3+ and fluorescence in situ hybridization (FISH)
positive), we started with the combination of docetaxel,
trastuzumab and pertuzumab. After 2 cycles the patient had a
partial response (PR). Currently, he has an ongoing PR 17 months
after start of treatment, and received 25 cycles. Side effects
consisted of a flare-up of radiotherapy toxicity induced by the
systemic treatment and a pre-aurical and retropharyngeal
abscess after 2 cycles. After 10 cycles the patient developed
erysipelas of the right side of his face. At this moment he as a
very good quality of life with no adverse events and a WHO
performance score of 0.
Case 2. A 48-year-old woman was diagnosed with a pT3N1M0
SDC ex pleomorphic adenoma. Primary treatment consisted of a
right parotidectomy with homolateral neck dissection, followed
by adjuvant radiation therapy. Fifteen months after the initial diag-
nosis multiple pulmonary metastases were detected. Because of
strong HER2 overexpression and amplification (IHC 3+ and FISH
positive) and only weak AR expression, palliative treatment with
the combination of docetaxel, trastuzumab and pertuzumab was
initiated. The evaluation CT-scan showed SD with a decrease in
the sum of target lesions by 22%. After the sixth cycle she devel-
oped erysipelas of the right side of her face. Eight months after
start of treatment, progression of pulmonary metastases was
detected. Trastuzumab en pertuzumab were stopped and ADT
Table 1
Literature review on HER2-targeted therapies in metastatic salivary duct carcinoma.a
Author Study Number of patients Therapy Clinical benefit Median PFS
Agulnik et al. [12] Phase II trial 4 Lapatinib No CR or PR Unknown
Limaye et al. [13] Case series 5 Trastuzumab, paclitaxel and carboplatin 1  CR
2  PR
2  PD
18 months
Perissinotti et al. [14] Case series 11 3 patients: Trastuzumab only 3  SD Unknown
8 patients: Trastuzumab and chemotherapyb 2  PR
3  SD
5  PD
1  non-evaluable
Falchook et al., [15] Phase I trial 3 Trastuzumab, lapatinib and bevacizumab 1  PR
1  SD
1  PD
3 months
De Block et al. [16] Case series 3 Trastuzumab and chemotherapyb 3  PR 11 months
Takahashi et al. [9] Phase II trial 45 Trastuzumab and docetaxel 31  CR/PR? Response rate 69% 11.3 months
CR: complete remission, PR: partial response, SD: stable disease, PD: progressive disease, PFS: progression free survival.
a Case-reports were excluded.
b Different combinations of chemotherapy were used.
Fig. 1. (a) Chest CT with a section width of 5 mm, pulmonary window, after intravenous contrast administration of the second patient before starting trastuzumab-
emtansine. Pulmonary metastasis with cavitation in the left lower lobe of 29 mm in the largest axial direction and a more opacified metastasis in the right lower lobe
measuring 34 mm in the largest axial direction. (b) Chest CT with a section width of 5 mm, pulmonary window, after intravenous contrast administration of the second
patient after 4 months of treatment with trastuzumab-emtansine. Pulmonary metastasis in the left lower lobe measuring 16 mm. The pulmonary metastasis in the right
lower lobe is immeasurable.
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was started, but the first evaluation after 3 months showed an
increase of the pulmonary lesions and a new brain metastasis.
Therefore, ADT was stopped and she received stereotactic radiation
therapy on the brain metastasis. The primary tumor was analyzed
with the ‘Radboud Cancer Hotspot gene panel’, but no druggable
mutations were found. Leaving HER2 as the only druggable target,
we decided to start with trastuzumab-emtansine once every
3 weeks. After 6 cycles of trastuzumab-emtansine she had a PR
with a decrease in the sum of target lesions of 70% (Fig. 1).
Currently, after 12 cycles she has an ongoing PR.
Discussion
We presented two patients with metastatic SDC, which were
treated with the combination of docetaxel, trastuzumab and per-
tuzumab. On this regimen, one patient has an ongoing PR after
17 months of treatment and one patient had PD after 8 months.
In the last patient, we show that a subsequent line of HER2-tar-
geted therapy can be beneficial, as this patient has a sustained
PR after 8 months of treatment with trastuzumab-emtansine.
Remarkably, both patients developed erysipelas at the site of
the resected primary tumor. Erysipelas is a known side effect of
trastuzumab [11] but not for pertuzumab. Whether dual HER2
blockade increases the risk of this side effect, especially in a previ-
ously operated and irradiated area, is not known.
In conclusion, we showed that dual HER2 blockade and multiple
lines of HER2-targeted therapies can be beneficial to patients with
metastatic HER2-positive SDC. More research is needed to estab-
lish the advantage of the combination of docetaxel, trastuzumab
and pertuzumab over docetaxel and trastuzumab alone. The effi-
cacy of trastuzumab-emtansine in SDC has to be assessed, however
we showed efficacy in one patient after PD with dual HER2
blockade.
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